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ABSTRACT
Diabetes management is firmly based within 
the primary care community. Landmark 
randomized, controlled trials have demonstrated 
that even modest reductions in glycated 
hemoglobin (HbA1c) can yield improvements in 
economic and medical end-points. Diabetes is a 
chronic, progressive disease associated with loss 
of pancreatic β-cell function. Therefore, most 
patients will eventually require insulin therapies 
in order to achieve their individualized targeted 
HbA1c as their β-cell function and mass wanes. 
Although clinicians understand the importance 
of early insulin initiation, there is little agreement 
as to when to introduce insulin as a therapeutic 
option. Once initiated, questions remain as to 
whether to allow the patients to self-titrate their 
dose or whether the dosing should be tightly 
regulated by the clinician. Physicians have 
many evidence-based basal insulin protocols 
from which to choose, all of which have been 
shown to drive HbA1c levels to the American 
Diabetes Association target of ≤7%. This article 
will discuss ways by which insulin therapies 
can be effectively introduced to patients within 
busy primary care practices. Published evidence-
based basal insulin protocols will be evaluated 
for safety and efficacy.
Keywords: algorithms; basal insulin; physiologic 
insulin replacement therapy
INTRODUCTION
With over 90% of all Americans being managed 
for diabetes by their primary care physicians 
(PCPs), a substantial amount of American 
healthcare dollars could be saved by initiating 
intensified care with family physicians and 
internists.1 Of the $174 billion total cost for 
managing patients with diabetes in 2007, $58 
billion was directed towards treating long-
term complications.2 Diabetes contributes to 
prolonged hospital admissions, more frequent 
outpatient clinic visits, as well as emergency 
department and home healthcare utilization.2
In 2007, 23% of inpatient costs in the United 
States were attributed to diabetes-related 
illnesses.2 Although there is general agreement Diabetes Ther (2011)  2(1):40-50. 41
among patients and practitioners that PCPs are 
overworked and undercompensated, the desire 
to become more adept at managing diabetes 
appears to be becoming a popular trend. 
In some communities, a patient may wait 
3 months or longer before they have their initial 
consultation visit with an endocrinologist. Out 
of necessity, more community-based PCPs have 
become as proficient at initiating and titrating 
insulin as their referral sources, thus allowing 
patients to receive timely and aggressive diabetes 
management. Improvement in economic and 
medical end-points can be achieved with even 
modest reductions in glycated hemoglobin 
(HbA1c). This article will discuss ways by which 
intensive insulin therapy can be rationally 
introduced to patients in busy primary care 
practices, many of which do not have access to 
certified diabetic educators, nurse practitioners, 
or physician assistants. In these practices, the 
physician alone may be the designer, presenter, 
and educator for a given intensification regimen. 
These treatment protocols can be introduced 
in a rapid and efficient manner allowing 
the physician to move quickly to their next 
patient. 
PHYSIOLOGIC INSULIN-
REPLACEMENT THERAPY OVERVIEW
The ultimate goal of insulin-replacement therapy 
is to mimic the normal insulin response in both 
the fasting and postprandial state. Euglycemic 
individuals produce enough endogenous 
insulin from their functioning pancreatic β cells 
to maintain their glucose levels within the 
narrow range of 85-140 mg/dL.3 The glucose 
concentration normally varies little despite 
wide daily fluctuations in food intake and 
activity level. Insulin secretion from the β cells 
and insulin action at peripheral sites, such as 
the liver, skeletal muscle, and adipose tissue, 
are uniquely pared to provide minimization of 
diurnal glycemic variability. Following a meal, 
the postprandial glucose peak mostly occurs 
between 1 and 2 hours with a mean peak time of 
75 minutes.4 Rapid-acting insulin analogs display 
a maximum effect at approximately 100 minutes 
after a subcutaneous injection.4 Therefore, 
injection of a rapid-acting insulin analog should 
occur 15 minutes prior to eating so that the 
insulin peak action is better synchronized with 
the glycemic excursions after a meal. This will 
minimize the anticipated postprandial glycemic 
spike.4
Insulin is normally secreted in two phases. 
In the fasting state, insulin is produced at the 
rate of approximately 1 unit per hour in order 
to minimize the effect of hepatic glucose 
production.3 Basal insulin limits lipolysis and 
free fatty acid production, which, in susceptible 
individuals, induces insulin resistance in the 
postabsorptive state.3 Eating prompts a five- to 
tenfold rise in portal vein insulin concentration 
to minimize postprandial hyperglycemia.3 First-
phase insulin response occurs quickly just prior 
to eating and ends rapidly so that the body does 
not experience an abrupt rise in blood glucose 
levels. As the carbohydrates for the meal are 
consumed, a second-phase insulin response 
continues from the β cells until all carbohydrates 
have been absorbed from the gastrointestinal 
tract and the plasma glucose levels have 
normalized. The postabsorptive state may last up 
to 6 hours depending on the content of the meal. 
Food that is high in fat (such as pizza) may delay 
the absorption of carbohydrates significantly.3
Patients with type 2 diabetes have peripheral 
insulin resistance and inadequate insulin 
secretion by pancreatic β cells. During meals, the 
reduced first-phase insulin secretion results in 
postprandial hyperglycemia and a 35% decrease 
in hepatic glycogen storage.5 A 55% increase 
in nocturnal hepatic gluconeogenesis drives 42 Diabetes Ther (2011)  2(1):40-50.
excessive glucose production5 favoring fasting 
hyperglycemia. Ultimately, genetically prone 
individuals with progressive β-cell dysfunction 
experience a state of chronic hyperglycemia that 
is unresponsive to oral antidiabetic agents. In 
order to achieve the recommended HbA1c target 
of 6.5%-7%, exogenous insulin therapy must 
often be initiated.6
Physiologic insulin-replacement therapies in 
patients with type 2 diabetes include basal plus 
bolus regimens as well as mixed insulins and 
insulin pump therapies. Newer insulin analogs 
are preferred over human insulin preparations 
due to their increased predictability of absorption, 
minimization of hypoglycemic risk, and 
improved day-to-day intrasubject variability.7
Keys to Initiating Insulin Therapy in 
Primary Care
There is little agreement as to the most 
appropriate time to initiate insulin therapy in 
patients with type 2 diabetes. However, the 
American Association of Clinical Endocrinologist 
Consensus Panel Statement for Glycemic Control 
provides some guidance by recommending 
that insulin should be considered for any 
type 2 patient having an HbA1c >9% or any 
symptomatic individual with an HbA1c >8.5%.8 
Increasing prescriber’s acceptance of these expert 
opinions would seem prudent, as early insulin 
initiation appears to have a significant glucose 
lowering effect and can minimize long-term 
complications related to chronic hyperglycemia.9
As PCPs express concern about lack of resources, 
reimbursement, or lack of experience with 
insulin initiation, diabetes intensification is 
too often delayed. Simplifying the treatment 
algorithms for initiating and titrating insulin 
may entice patients as well as prescribers towards 
earlier intensification of treatment regimens. 
Early use of insulin therapy is often necessary 
for timely achievement of targeted glycemic 
goals including HbA1c, as well as fasting and 
postprandial glucose levels. For patients with 
type 2 diabetes, glycemic targets can be achieved 
using a basal insulin plus oral agents, basal-bolus 
insulin, and premixed insulin analogs.3 Table 1 
lists the strategies that should be considered 
when initiating insulin therapy for patients with 
type 2 diabetes. 
Approximately 10% of patients diagnosed 
with type 2 diabetes actually have latent 
autoimmune diabetes in adults (LADA).10 This 
slowly progressive form of autoimmune diabetes 
is characterized by mature age at diagnosis, the 
presence of pancreatic autoantibodies (glutamic 
acid decarboxylase-65 antibodies), and the lack 
of absolute insulin requirement at diagnosis. 
Although LADA patients present with more 
preserved β-cell function than those with classic 
type 1 diabetes mellitus, these individuals 
experience a rapid and progressive loss of 
β-cell function, necessitating intensive insulin 
intervention. Oral agents are not effective at 
maintaining glycemic control in patients with 
LADA. 
Basal Insulin Intensification Protocols
The American Diabetes Association consensus 
statement for managing hyperglycemia 
recommends that basal insulin be initiated if a 
patient is symptomatic or has an HbA1c >8.5% 
while using metformin in conjunction with 
lifestyle intervention.6 Several recently published 
studies have demonstrated the safety and efficacy 
of patient-directed basal insulin algorithms.11-14
The primary objective of the AT.LANTUS trial 
(A Trial Comparing Lantus Algorithms to Achieve 
Normal Blood Glucose Targets in Subjects With 
Uncontrolled Blood Sugar) was to compare the 
safety and efficacy of insulin adjustments. Over 
a period of 26 weeks, 4500 patients were given Diabetes Ther (2011)  2(1):40-50. 43
insulin glargine (Lantus) once daily.13 Half the 
patients were randomized to clinic-based weekly 
dose adjustments based upon the average blood 
glucose levels taken 3 days prior to the week’s 
end as shown in Table 2.13 In AT.LANTUS the 
incidence of nocturnal, severe, and symptomatic 
hypoglycemia were not statistically significant 
between the two groups of patients. In the 
patient-led titration algorithm, the fasting blood 
sugar levels (achieved by the patients) were 
lower than those in the physician-led titration 
algorithm. This was also evidenced with a higher 
dose of insulin that was used in the patient-
led treatment algorithms. The most significant 
change was a significant drop in HbA1c in the 
patient-led titration algorithm. The reduction in 
HbA1c for the patient self-directed protocol was 
–1.22% vs. –1.08% for the clinic-based algorithm 
(P<0.001). These compelling data suggest that 
treatment goals can be achieved by patients 
who are empowered to titrate their own insulin 
regimens. 
The Canadian Insight Trial,12 evaluated 
the efficacy of a simplified basal insulin dose 
titration regimen initiated within either an 
endocrine or primary care setting. Four hundred 
and five patients with type 2 diabetes with 
HbA1c 7.5%-11% and taking zero to one oral 
agents were randomized to receive either basal 
insulin glargine via a self-titration algorithm 
or conventional therapy with physician-
adjusted doses of oral agents for 24 weeks. The 
primary outcome was the time to achieve two 
consecutive HbA1c values ≤6.5%. The patients 
Table 1. Strategies for initiating and titrating insulin for treatment-naive patients with type 2 diabetes.
•	 Suggest	that	insulin	will	help	patient	achieve	glycemic	targets	and	minimize	the	risk	of	long-term	complications.
•	 Allow	patients	to	actively	participate	in	their	insulin	dose	titration.	
•	 Always	praise	patients	on	insulin	for	their	efforts	at	achieving	their	glycemic	targets	at	their	visits.	Remember,	patients	
who	are	using	insulin	do	not	have	normal	functioning	pancreases.	They	are	calculating	their	doses	of	insulin,	themselves,	
perhaps	multiple	times	each	day.	Insulin	prescribers	should	do	everything	possible	to	help	them	become	successful	in	
insulin dosing. 
•	 Individualize	therapy	to	meet	the	needs	of	each	patient.	Determine	which	treatment	algorithm	might	work	best	for	every	
patient.
•	 Enforce	and	emphasize	the	importance	of	lifestyle	intervention.	This	should	minimize	weight	gain	and	reduce	
postprandial	glucose	excursions.	
•	 Consider	having	group	office	visits	run	in	conjunction	with	a	certified	diabetic	educator.	Often	8-20	patients	can	be	seen	
at	these	group	visits,	which	are	time	efficient	and	reimbursable	by	third	party	payers.	
•	 Provide	each	patient	with	an	individualized	written	insulin	protocol	to	which	they	can	refer	to.	
•	 Prescribe	insulin	pen	devices	whenever	possible.	Dose	titration	of	insulin	is	much	more	accurate	with	pens	than	with	vials	
and syringes.
•	 Teach	patients	on	the	importance	of	identifying	and	appropriately	managing	hypoglycemic	events.
•	 When	initiating	basal	insulin	use	0.4	units/kg/day	as	your	starting	dose.	Continue	metformin	if	possible.	
•	 If	patient	requires	more	than	60	units	of	basal	insulin	per	day	and	their	HbA1c	is	>7%,	add	a	rapid	acting	insulin	analog	to	
the	largest	meal	of	the	day.	The	dose	for	the	rapid	acting	insulin	is	0.1	units/kg	per	meal.
•	 If	HbA1c	is	not	reduced	to	target	after	3	months	of	basal	plus	bolus,	add	a	second	injection	at	the	next	largest	meal	of	the	
day.	Repeat	the	HbA1c	at	3	months	and	if	still	above	target	add	a	third	mealtime	injection.	
•	 Patients	on	basal	bolus	insulin	therapy	should	consider	modified	paired	glucose	testing	in	order	to	fine-tune	their	
treatment regimen.
HbA1c=glycated	hemoglobin.44 Diabetes Ther (2011)  2(1):40-50.
randomized to the insulin glargine group were 
initiated on 10 units of insulin to be taken at 
a consistent time each evening before bedtime. 
Fasting glucose levels were checked daily. The 
dose of insulin glargine was increased 1 unit each 
evening until patients achieved a fasting glucose 
level of 99 mg/dL. The PCPs achieved a greater 
reduction in fasting plasma glucose with insulin 
glargine than with oral agents (fasting plasma 
glucose: –74.5 mg/dL vs. –44.1 mg/dL, P=0.0001; 
specialists: –62.4 mg/dL vs. –39.4 mg/dL, 
P=0.0013). The PCPs reduction in HbA1c was also 
superior to that achieved by the specialists when 
insulin use was compared with that of oral agent 
dose titration (–1.64% vs. –1.26%, P=0.0058; 
specialists –1.41% vs. –1.24%, P=0.3331). PCPs 
were more aggressive in their use of insulin, 
whereas the specialists used more oral agents. 
No differences in the rates of hypoglycemia 
were noted between the cohorts. The Canadian 
Insight Trial suggests that PCPs could easily and 
safely implement a patient-driven, single-unit, 
basal dosing-adjustment protocol within their 
clinical practice. 
The PREDICTIVE 303 protocol14 (The 
Predictable Results and Experience in Diabetes 
through Intensification and Control to Target: 
An International Variability Evaluation 303 
Study) is a patient-driven algorithm tested 
within the primary care setting. The primary 
end-point of this safety and efficacy study 
was to determine whether treatment-naive 
patients could be “empowered” to adjust their 
insulin dose simply by monitoring their fasting 
glucose levels. In addition, could their dosing 
adjustments result in improved glycemic 
targets and less hypoglycemia compared to 
a standardized clinic-based dosing protocol? 
A total of 5619 patients with type 2 diabetes, 
having an HbA1c ≤12% were randomized with 
receive insulin detemir via a pre-determined, 
self-adjusted protocol (Table 3)14 or one that 
was physician directed. After 26 weeks both 
cohorts demonstrated equal HbA1c reductions 
of approximately 0.6% from the mean baseline 
of 8.5%. Although the incidence of overall 
hypoglycemia was not statistically significant 
between the two groups, the patient-directed 
Table 2. Insulin	glargine	(Lantus)	dosing	regimen	algorithms	applied	to	achieve	normal	blood	glucose	targets	in	subjects	with	
uncontrolled	blood	sugar	with	type	2	diabetes	mellitus.13 (A)	Clinic-based	dosing	protocol.	(B)	Patient-driven	protocol.
(A)
Self-monitoring fasting blood glucose (mg/dL)  Units/day increase insulin dose
≥180	 8
140-180	 6
120-140	 4
100-120	 2
•	 Initial	dose	insulin	glargine	10	units	at	bedtime.	Adjust	weekly.
•	 Measurements	used	to	calculate	dose	adjustments	were	monitored	3	days	prior	to	dose	titration.	
•	 No	increase	in	dose	permitted	if	any	blood	glucose	reading	is	<72	mg/dL.
(B)
•	 Initial	dose	glargine	10	units	at	bedtime.
•	 Self-titrate	two	units	every	3	days	to	target	fasting	blood	glucose	<100	mg/dL	(equivalent	to	the	highest	FBG	value	over	
the	previous	7	days).Diabetes Ther (2011)  2(1):40-50. 45
cohort demonstrated slightly higher rates of 
nocturnal hypoglycemia.14
In this subgroup analysis of insulin-
naive patients (ie, those only receiving oral 
antidiabetics prior to enrolment in the study), 
the overall hypoglycemia rates at baseline were 
lower than in the full population and remained 
relatively stable after 26 weeks. At 26 weeks, there 
was no significant difference between the two 
arms (P=0.46). Rates of nocturnal hypoglycemia 
were low at baseline and week 26 in both the 
self-adjusted and investigator-adjusted groups. 
The rate of nocturnal hypoglycemia at 26 weeks 
was significantly lower in the investigator-
adjusted group than in the self-adjusted group 
(P=0.03). The PREDICTIVE 303 study, therefore, 
suggests that patients who are insulin naive can 
safely adjust their insulin doses when given a 
specific goal-directed algorithm.14
However, PREDICTIVE 303 was not a treat-
to-target study, but a study powered to evaluate 
the safety and efficacy of self-dose adjustment 
empowerment within a primary care setting. 
In order to determine whether patients could 
use the PREDICTIVE 303 protocol to achieve an 
aggressively targeted HbA1c, the TITRATE study 
was developed.12 TITRATE compared the efficacy 
and safety of two fasting plasma glucose titration 
targets (80-110 mg/dL and a more aggressive 
target of 70-90 mg/dL) using a patient-directed 
treat-to-target algorithm for once-daily basal 
insulin in insulin-naive subjects with type 2 
diabetes. Two hundred and forty-four patients, 
who were suboptimally treated with oral agents 
and had HbA1c levels between 7% and 9%, 
were randomized to either the 80-110 mg/dL 
or the 70-90 mg/dL treatment arms. The dose 
titration for both arms of the study are shown 
in Table 4.11,12
 Overall, both treatment groups achieved a 
mean HbA1c level of 6.9% at the end of the 20 
week study. The majority of subjects in both 
titration groups also achieved the American 
Diabetes Association recommended HbA1c level 
of <7%. At the end of the study period, 64.3% 
of subjects in the 70-90 mg/dL cohort achieved 
HbA1c levels <7% compared with 54.5% of 
subjects in the 80-110 mg/dL group (95% Cl: 
1.03-3.37, odds ratio 1.86, P=0.04). The overall 
rates of hypoglycemia episodes were low and 
were comparable between treatment groups. A 
single event of major hypoglycemia was reported 
in the 70-90 mg/dL group. Mean weight changes 
Table 3. The	pre-determined,	self-adjusted	PREDICTIVE	
303	protocol*.14
Average fasting glucose  Basal insulin dose adjustment 
over previous 3 days  based on glucose average
<80	 Reduce	dose	by	three	units
80-110	 Maintain	same	dose	of	insulin. 
	 (No	changes	needed.)
>110	 Increase	dose	by	three	units
*Patients	continued	their	oral	antidiabetic	doses	at	stable	
doses	during	the	trial.	Dose	reductions	or	discontinuation	
of sulfonylureas and glinides were permitted if patients 
were	experiencing	hypoglycemia.	The	initial	dose	of	insulin	
detemir	was	0.1-0.2	units/kg	or	10	units	daily	at	dinner	or	
bedtime.
Table 4. The	TITRATE	protocol*.11
Average fasting plasma  Insulin detemir dose 
glucose of 3 consecutive days  adjustment
Using 70-90 mg/dL target 
<70	 –3	units
70-90	 No	adjustment
>90	 +3	units
Using 80-110 mg/dL target
<80	 –3	units
80-110	 No	adjustment
>110	 +3	units
*Patients	continued	their	oral	antidiabetic	doses	at	stable	
doses	during	the	trial.	Dose	reductions	or	discontinuation	
of sulfonylureas and glinides was permitted if patients were 
experiencing	hypoglycemia.	The	initial	dose	of	insulin	
detemir	was	0.1-0.2	units/kg	or	10	units	daily	at	dinner	or	
bedtime.46 Diabetes Ther (2011)  2(1):40-50.
from baseline to the end of the study were 
small and did not differ significantly between 
treatment groups. The TITRATE study, therefore, 
demonstrates that lowering the fasting glucose 
target using a self-directed algorithm with once-
daily insulin detemir is safe and increases the 
likelihood of achieving the American Diabetes 
Association target HbA1c level of <7%. Despite 
the aggressive fasting blood glucose targets set by 
TITRATE, hypoglycemia rates were minimal.12
As diabetes is a progressive disorder, pancreatic 
β-cell dysfunction necessitates the addition 
of mealtime insulin to minimize postprandial 
excursions.15,16 Glucose fluctuations during the 
postprandial period elicit more oxidative stress 
than chronic, sustained hyperglycemia and 
can lead to endothelial dysfunction, vascular 
inflammation, and microvascular complication.17
In turn, endothelial dysfunction has been 
implicated in the development of vascular 
disease, such as atherosclerosis.18 Pharmacologic 
interventions (eg, rapid-acting insulin analogs) 
reduce oxidative stress, vascular inflammation, 
and improve endothelial dysfunction.19
The Treating To Target in Type 2 Diabetes 
Study (the 4-T Study), provides some insight into 
when insulin should be initiated in patients and 
at what time during the course of their disease 
prandial insulin might be initiated.20 Over 700 
individuals with type 2 diabetes who were on 
dual oral agent therapy were randomized into 
this study. They were randomized into the three 
groups. One group was randomized to biphasic 
insulin aspart 70/30 twice daily. The second group 
was randomized to prandial insulin, aspart, three 
times daily. The third randomization was using 
basal insulin detemir once daily at bedtime. 
The trial used a clinically relevant protocol with 
clinic visits every 3 months, a schedule similar 
to that routinely followed in the primary care 
setting. After 1 year, patients who continued 
to have unacceptable rates of hyperglycemia 
(defined as HbA1c >10% after one measurement, 
two consecutive HbA1c measurements ≥8% 
at or after 24 weeks of therapy, or an HbA1c 
>6.5% at the end of year 1) were eligible for 
intensification of their insulin regimens. 
Therapy with sulfonylurea was replaced with an 
additional type of rapid acting or mixed insulin 
regimen as follows: (1) insulin aspart was added 
three times daily to the insulin detemir-initiated 
arm starting with 10% of the current total daily 
basal dose (minimum of four units; maximum 
of six units).20 (2) insulin detemir (10 units) was 
added at bedtime to the insulin aspart-initiated 
arm; (3) insulin aspart was added at midday 
to the insulin aspart mix 70/30-initiated arm 
starting with 10% of the current total daily dose 
(minimum of 4 units; maximum of 6 units). This 
practice is not typically prescribed in the US.
The primary outcome of the first 4-T Study 
published in 200721 was HbA1c <6.5%. There 
were small but significant differences between 
the three groups. The group with the highest 
HbA1c was those individuals randomized to 
basal insulin at bedtime and those with the 
lowest HbA1c had received prandial insulin. 
However, none of the groups achieved the 
target hemoglobin HbA1c of <6.5%. As expected, 
basal insulin resulted in optimal reduction of 
fasting blood glucose, whereas prandial insulin 
improved postmeal glucose excursions better 
than basal or mixed insulins. Less weight gain 
and fewer episodes of hypoglycemia were noted 
in the basal insulin cohort. Thus, after 1 year, 
the conclusions of the 4-T Study were as follows: 
(1) regimens using biphasic or prandial insulin 
reduced HbA1c to a greater extent than basal, 
but were to be associated with a greater risk of 
hypoglycemia and weight gain; (2) most patients 
are likely to require more than one type of 
insulin to achieve target HbA1c levels over time 
as very few individuals were able to maintain 
their HbA1c levels at <6.5%. Diabetes Ther (2011)  2(1):40-50. 47
The investigators noted a progression in the 
disease process for patients with type 2 diabetes 
and an inability to reduce a rise in HbA1c; 
therefore, patients were randomized to be placed 
on prandial insulin.21 After an additional 2 years 
in the 4-T Study, the HbA1c levels were identical 
between all three groups. What did reach 
statistical significance was the fact that those 
individuals initiated on basal insulin therapy 
alone at the end of 3 years had less grade 2 or 
grade 3 hypoglycemias, the more severe forms 
of hypoglycemia. This group also demonstrated 
the least amount of weight gain during the 3 
year study. 
The overall aggregate HbA1c at the conclusion 
of the 3 year 4-T Study was 6.9% and did not 
differ significantly between treatment groups.21 
However, patients commencing therapy with 
basal or prandial insulin more often achieved 
glycemic targets than those initiating therapy 
with biphasic insulin. The lowest weight gain 
and lowest rate of hypoglycemia occurred in 
the insulin detemir plus insulin aspart group, 
with 63% of patients achieving HbA1c ≤7%. 
Finally, the 4-T Study supports starting insulin 
therapy with once-daily basal insulin and adding 
prandial insulin if glycemic goals are not met 
within 1 year. 
Basal insulin was the most effective treatment 
regimen within the 4-T Study protocol because 
the insulin dose was progressively increased 
towards specific fasting and postmeal targets. 
Self-blood glucose values of each subject 
were analyzed by a computer management 
system at the time of each visit.21 An insulin-
dosing regimen was then prescribed to target 
fasting glucose levels of 72-99 mg/dL and 2 
hour postprandial levels of 90-126 mg/dL. 
Investigators and patients were encouraged 
to vary suggested insulin doses, as clinically 
appropriate, and to amend the doses between 
visits. Hypoglycemia was categorized as grade 
1 (symptoms only) if a patient had symptoms 
with a self-measured capillary glucose level 
of 56 mg/dL or more, grade 2 (minor) if the 
patient had symptoms with a self-measured 
capillary glucose level of <56 mg/dL, or grade 3 
(major) if third-party assistance was required. 
Unfortunately, the computer-generated dosing 
protocol suggestions are not clinically available 
to practicing physicians and were used solely for 
those investigators and patients enrolled in the 
4-T Study. Nevertheless, initial intensification 
of therapy in patients with poorly controlled 
type 2 diabetes with basal insulin appears to 
be a prudent choice. Fasting hyperglycemia 
contributes more than postprandial 
hyperglycemia to HbA1c levels during periods of 
poor glycemic control.22
CHOOSING THE OPTIMAL 
INSULIN-REPLACEMENT 
PROTOCOL
Optimal diabetes management should be 
patient-centered. With the exception of the 
4-T Study, all of the protocols mentioned in 
this manuscript allowed patients (including 
those who are insulin naive) to titrate their own 
insulin regimens. Insulin pen delivery devices 
should be used to titrate and administer insulin 
due to their ease of use and dosing accuracy. 
Patients may find increasing insulin 1 to 2 units 
more difficult when using a syringe and vial 
versus dosing with a pen device.23 One should 
consider stopping oral agents when insulin is 
initiated. However, continued use of metformin 
appears to be a rational choice as metformin may 
minimize weight gain associated with insulin 
use. Metformin has also been associated with 
a lower cancer mortality rate compared with 
nonuse of the drug.24
Using the TITRATE protocol as a model, 
one would initiate basal insulin at the dose 48 Diabetes Ther (2011)  2(1):40-50.
of 0.1-0.2  units/kg once daily (usually at 
bedtime). The desired targeted fasting blood 
glucose level could be identified for the patient. 
Although TITRATE had a very aggressive target 
of 70-90 mg/dL or 80-110 mg/dL, certainly less 
stringent glycemic goals could be recommended 
to each patient based upon individualized 
treatment targets, duration of diabetes, age, 
history of hypoglycemic unawareness, or history 
of cardiovascular disease.   
The most important aspect of dose titration 
is minimization of the risk of hypoglycemia. 
The PREDICTIVE 303 and TITRATE studies 
both demonstrated that overall and nocturnal 
hypoglycemia rates are minimized using the 
protocols shown in Tables 3 and 4.11-14
Perhaps the easiest and safest protocol to 
initiate would mirror that used in the Canadian 
Insight Trial (Table 5).12 The starting dose of 
insulin would be very conservatively placed 
at 10 units to be given at a consistent time of 
the day. The patient would monitor their blood 
glucose level on a daily basis and continue to 
increase their basal insulin dose until they reach 
a fasting glucose target of <100 mg/dL. 
If the HbA1c remains above target at that time, 
prandial insulin injected 10-15 minutes prior to 
the patient’s largest daily meal should be added 
to the patient’s regimen. The HbA1c should be 
monitored once again after 3 months. If the 
HbA1c remains above target, another mealtime 
insulin injection for the second largest meal of 
the day should be initiated. If after an additional 
3 months, the HbA1c remains elevated, a third 
mealtime injection should be prescribed. While 
the mealtime regimen is being adjusted, the 
PREDICTIVE 303 protocol should be continued 
allowing patients to continually monitor and 
adjust all of their daily insulin doses.14 
CONCLUSION
Basal insulin regimens are a safe and effective 
means by which hyperglycemia can be initially 
managed within the primary care setting. 
Allowing patients the opportunity to adjust 
and titrate their basal insulin dose using 
individualized treatment protocols will allow 
most patients to achieve their glycemic targets 
without having to refer them to specialists. 
The safety and efficacy of different aggressive 
treatment algorithms, many of which have 
been clinically tested within the primary care 
arena, should provide physicians and their 
patients with the encouragement they need to 
aggressively manage hyperglycemia in a timely 
manner. 
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Table 5. Basal	insulin	single	unit	dosing	protocol.12
•	 Initiate	basal	insulin	at	10	units.	
•	 Administer	insulin	injection	at	the	same	time	each	day	
as	basal	insulin	duration	is	24	hours.
•	 Monitor	your	blood	glucose	level	after	fasting	each	
morning. 
•	 Each	night	increase	dose	until	your	fasting	glucose	level	
is	below	100	mg/dL.
•	 Notify	your	physician	if	you	feel	shaky,	sweaty,	
confused,	or	have	a	blood	glucose	level	<56	at	any	time	
of the day.Diabetes Ther (2011)  2(1):40-50. 49
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